

Article

Integration of Multi-Omics Biomarkers in Cancer Diagnostics: Clinical Laboratory Applications, Analytical Challenges, and Future Directions : Review article

Ibrahim Ayad jihat¹, Zainab Ahmed Mustafa², Amani Naama Mohammed³

¹Department of chemistry and biochemistry, Al-Zahraa college of medicine, University of Basrah, Iraq

²Department of chemistry and biochemistry, Al-Zahraa college of medicine, University of Basrah, Iraq

³Department of chemistry and biochemistry, Al-Zahraa college of medicine, University of Basrah, Iraq

*Correspondence: ibrahim.jihat@uobasrah.edu.iq¹, zainab.mustafa@uobasrah.edu.iq², amani.mohammed@uobasrah.edu.iq³

Citation: jihat I. A., Mustafa Z. A., and Mohammed A. N. Integration of Multi-Omics Biomarkers in Cancer Diagnostics: Clinical Laboratory Applications, Analytical Challenges, and Future Directions : Review article. American Journal of Biomedicine and Pharmacy 2026, 3(5), 124-136.

Received: 10th Apr 2026

Revised: 21th Apr 2026

Accepted: 4th May 2026

Published: 24th May 2026



Copyright: © 2026 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

Abstract: The diagnosis of cancer is shifting towards paradigm with integration of multi-omics that includes genomics, transcriptomics, proteomics, metabolomics and epigenomics. Integrated platforms can deliver a comprehensive molecular map of the tumor, with important insights into early detection, prognosis stratification and the accuracy of therapeutic response prediction. But, despite the huge potential, multi-omics biomarkers are not yet in daily use in clinics due to a number of systemic problems. These include pre-analytical variability in sample preparation, lack of standardized analytical protocols, high-dimensional bioinformatics and considerable regulatory and economic hurdles. In this regard, artificial intelligence (AI) and machine learning (ML) have proven to be game-changers, providing the computational capacity needed to combine heterogeneous data and uncover nuanced biomarker patterns that underlie personalized oncology. Multi-omics tools, through their ability to provide longitudinal monitoring, allow to adapt the therapeutic approach to the individual's biological profile, maximizing the benefits of the treatment and minimizing of the ineffective treatments. To achieve this in a clinical lab setting, automated workflows and stringent quality control protocols must be created and implemented to meet regulatory compliance requirements. This review aims to discuss the present status of multi-omics in oncology, explore current gaps in translation and present a roadmap for the successful integration of AI-driven precision medicine into next-generation oncology.

Keywords: Multi-Omics, Biomarkers, Cancer Diagnostics, Precision Oncology, Clinical Laboratory, Artificial Intelligence, Translational Research

Introduction

Cancer is a leading cause of morbidity and mortality in various populations and continues to have a significant effect on the global health system. While extensive research effort over the last 40 years and the implementation of new screening and therapeutic pathways have been undertaken, the burden of oncological diseases is still a very strong challenge for public health systems all over the world [1]. The problem is that malignant transformation is incredibly complex from a biological

perspective, and is inherently heterogeneous [2]. Such traits can make standard diagnostic tools, often based on broad, "one size fits all" metrics, less effective to meet the complex needs of precision medicine today. There is therefore a clinical need to develop more comprehensive, multi-dimensional biomarker strategies that are beyond the limitations of current single analyte assays [3][4]. The clinical laboratory medicine has traditionally been confined to the single-omics approaches. This has mostly focused at the level of isolated genomic sequencing or on the quantification of specific markers, such as PSA or CEA [5]. Although these tools have given us some basic insights, they capture only a small, localized, piece of the whole picture of a biological story, and don't always capture the dynamic interactions between the various molecular layers or the evolving nature of the tumor microenvironment [6]. As a contrast, the advent of multi-omics integration provides a systems-level view that integrates genomics, transcriptomics, proteomics, metabolomics and epigenomics. Combining information from these different levels of biology can help researchers gain a comprehensive view of the tumor's biology, which helps inform diagnosis and prognosis with greater accuracy [7][8]. These integrative viewpoints are now starting to be an important part of the clinical picture in different areas of oncology. In liver cancer, multi-omics platforms have emerged as transformative tools for achieving more accurate molecular subtyping, guiding personalized therapeutic decisions, and shaping overall prognosis. [9][10]. Similarly, in gastrointestinal oncology, the combination of omics approaches, across all fields, has been consistently better than the traditional clinical biomarkers. These technologies have defined new milestones for early detection and risk stratification using circulating tumor DNA (ctDNA) and extracellular vesicles (EVs) [11][12]. Moreover, the combination of liquid biopsy and integration of multi-omic data has given us a window into the living tumour in the fields of breast and prostate cancers. This has enabled the ability to monitor the evolution of clones in a minimally invasive way, detect treatment resistance in a timely fashion, and assess the likelihood of recurrence more accurately [13][14]. Technology-wise, the field is growing with the introduction of single-cell and spatial omics [15]. These new modalities enable the dissection of intratumoral heterogeneity at a cellular level, thus reflecting the spatial relationship of malignant cells and adjacent immune architecture [16]. But the transition from bench to bedside is still hindered with significant operational hurdles. The processing of vast amounts of data within the time constraints of a standard clinical lab is a challenging task [17]. Data heterogeneity, inter-platform reproducibility, and the lack of harmonized bioinformatics pipelines are some of the challenges that still prevent implementation [18][19]. Furthermore, the cost of these technologies is a major challenge to healthcare equity and access globally [20]. The potential and the gaps in multi-omics technologies give a reason to critically examine these biomarkers in perspective with the future of routine diagnostic procedures in oncology [21][22].

Overview of Omics Technologies in Oncology

Genomics: Deciphering the Blueprint and Clonal Evolution

At the core of oncology related genomics is the dissection of the cancer genome at high resolution in order to identify somatic driver mutations, copy number variations (CNVs) and complex structural rearrangements that drive the process of malignant transformation [23]. Next-Generation Sequencing (NGS) has revolutionised traditional single-gene assays, making high throughput multi-gene panels (NGMPs) a viable alternative for clinical use [24]. These panels can be used to identify actionable changes like ALK fusions in lung cancer and BRCA1/2 deficiencies in ovarian cancer, which will help in choosing targeted therapies [25][26]. In addition to the initial diagnosis, genomics has developed into the monitoring of the dynamic living tumour. Now the longitudinal monitoring of minimal residual disease (MRD) is available thanks to ultra-deep sequencing of circulating tumor DNA (ctDNA) and represents a very powerful tool to detect molecular recurrence early before clinical symptoms emerge [27]. In addition, new genomic markers, such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) are now well established markers for immune checkpoint inhibitor (ICI) response [28]. Regardless of this progress, the use of NGS in clinical practice is still dependent on strong bioinformatics support and the precise standardization of reporting of variants to reduce the problem of "Variants of Unknown Significance" (VUS) [29][30].

Proteomics: Functional Execution and Signaling Networks

Genomics gives the blueprint and Proteomics gives the functional execution of the cellular programmes. This field focuses on protein expression quantifications, protein post-translational modification (PTM) events (including phosphorylation and ubiquitination events) and the dynamic protein-protein interaction networks that contribute to phenotypic changes [31]. The key technology for the clinical proteomics field is still mass spectrometry (MS), in particular LC-MS/MS, which has the sensitivity needed to detect low-abundance proteins from tumors in complex biofluids such as plasma or cerebrospinal fluid (CSF) [32][33]. A proteomic analysis of biological samples is of special significance in oncology, since it captures in real time the functional changes that cannot be foreseen based on genomic analysis. Such as, drug resistance often occurs through activation of bypass signaling pathway that is mostly based on protein phosphorylation, which is not detected by DNA sequencing [34]. Proteogenomic studies are now filling this gap, leveraging protein signatures to supplement genomic information and uncover new therapeutic opportunities [35]. Yet, the clinical use of these is currently limited due to the large dynamic range of the human proteome and the absence of high-throughput protocols for their preparation which can be automated as are the pipelines in genomics [36][37].

Metabolomics: The Metabolic Fingerprint and Cellular Phenotype

Metabolomics provides a clear snapshot of the cellular phenotype by measuring small-molecule metabolites, which are indicators of metabolic reprogramming, a hallmark of malignancy. To thrive in their rapid proliferation, cancer cells have characteristic alterations in glycolysis, in lipid biosynthesis and in nucleotide metabolism – the Warburg effect. These alterations are reflected in a unique metabolic fingerprint that can be used to detect the onset of cancer and to track cancer therapy as it progresses in real time [38][39]. Functional assessments of tumor behavior can be performed through minimally invasive liquid biopsies using high-resolution techniques such as Liquid Chromatography-Mass Spectrometry (LC-MS) and Nuclear Magnetic Resonance (NMR) spectroscopy, in order to assess the behavior of the tumor [40]. In the liver, pancreatic cancer, and other cancers, certain metabolic fingerprints have demonstrated high diagnostic accuracy for distinguishing malignant lesions from inflammatory conditions [41]. However, there is a lot of preanalytical variation in the field that needs to be addressed to bring the field to the level of reproducibility necessary for routine clinical accreditation [42][43].

Epigenetics: The Regulatory Interface and Early Detection

Epigenetics studies changes in gene expression that occur without a change in the underlying genetic sequence – changes that are heritable and can be reversed such as DNA methylation, histone modification, chromatin remodeling. Epigenetic changes are frequently involved in the early stages of cancer pathogenesis, before genetic alterations, making epigenetic markers attractive markers for ultra-early cancer detection [44][45]. New techniques such as ATAC seq and bisulfite sequencing have transformed the mapping of chromatin accessibility and methylation in large-scale studies. The clinical applications of methylation assays are also beginning to demonstrate their value in determining the tissue of origin in cancers of unknown primary (CUP) [46]. Epigenetic signatures can further refine diagnostic panels by incorporating genomic and proteomic details, thus improving the ability to stratify patients for optimal treatment choices, including epigenetic modifiers and immunotherapies [47][48]. Main challenges include the technical variability of high-throughput methylation mapping, and the necessity of using standardized reference epigenomes from various populations [49].

Table 1. Comparative Table of Omics Technologies

Omics Type	Primary Focus	Key Techniques	Clinical Applications	Limitations
Genomics	DNA alterations (Mutations, CNVs)	NGS, PCR, WGS	Mutation detection, targeted therapy	Bioinformatics complexity, VUS
Proteomics	Protein expression & PTMs	LC-MS/MS, ELISA	Prognostic markers, therapy response	Sample complexity, dynamic range

Metabolomics	Metabolic profiling (Small molecules)	LC-MS, GC- MS, NMR	Early detection, metabolic phenotyping	Pre-analytical variability (Diet/Meds)
Epigenetics	DNA/Histone modifications	Methyl-Seq, ChIP-seq	Tissue of origin, early screening	Technical variability, tissue specificity

Materials and Methods

This article was done as a narrative review which summarises the current evidence on multi-omics integration in the context of cancer diagnostics and precision oncology. MethodsA structured literature search across major scientific databases such as PubMed, Scopus and Web of Science was performed using keyword combinations, including the terms “multi-omics,” “genomics,” “proteomics,” “metabolomics,” epigenomics, cancer biomarkers, precision oncology and clinical laboratory integration. Studies, review articles and translational research reports published in peer-reviewed journals were included when they concerned oncological applications of multi-omics technologies, artificial intelligence-driven biomarker discovery and clinical implementation frameworks. Given the advances in technologies such as liquid biopsy, high-throughput sequencing, mass spectrometry and epigenetic profiling in recent years relevant studies were selected focusing on diagnostic, prognostic and therapeutic applications. For data extraction, findings were grouped into main omics domains and relevant clinical uses such as early detection, risk stratification or prediction of the treatment response. MethodsA thematic synthesis approach was performed to combine heterogeneous evidence and find repeating patterns within molecular layers. Special consideration was focused on analytical barriers like data heterogeneity, pre-analytical variability and bioinformatics integration, as well as translational hurdles including regulatory compliance, cost-effectiveness and laboratory harmonization. The extracted data were then synthesized in a conceptual framework explaining the integration of multi-layered data using artificial intelligence and machine learning for clinical decision. This study did not generate primary experimental data, but was entirely based on published literature. Methods–The methodological approach addressed extensive coverage, in-depth comparison and interpretative synthesis to create a combined view of both the clinical relevance of multi-omics technologies and their future deployment within the oncology research field focus.

Results and Discussion

Multi-Omics Biomarker Discovery in Cancer

The Frontier of Early Detection: Integrated Liquid Biopsies

The clinical need for early cancer detection is determined by the fact that localized cancers have a different prognosis from metastatic cancers. Typical screening tests like the Prostate-Specific Antigen (PSA) or Carcinoembryonic Antigen (CEA) have a lag period for diagnosis and are not always highly specific, resulting in many false positives and invasive procedures. To overcome these restrictions, multi-omics approaches are being developed to detect “molecular echoes” that can be detected months or even years before the appearance of a macroscopic tumor. The fusion of these genomic changes together with epigenetic and proteomic signals in one assay is a critical aspect of this transformative approach. Targeted NGS is highly sensitive for detecting somatic mutations in cells collected from circulating tumor DNA (ctDNA) but in many cases of low shedding rates in early-stage tumors, it has limited sensitivity. CpG island hypermethylation and metabolic fingerprints combined with ctDNA methylation patterns specifically fragmentomics have greatly improved the detection of hepatocellular and breast carcinomas at stage I. In addition, high-resolution mass spectrometry (MS) can now be used to profile proteins, including those with low abundance, present in exosomes, and provide a dynamic signature of the systemic host-tumor interaction. Pan-cancer studies indicate that composite panels with genomic, methylomic and proteomic variables offer the greatest diagnostic accuracy for diverse patient cohorts.

Prognostic Stratification: Resolving Molecular Heterogeneity

A key to risk-adapted therapy is accurate prognosis. The TNM system is still used in clinic, but it often neglects the intrinsic molecular diversity that drives different clinical courses between two patients with the same clinical stage of disease. Multi-omics profiling is a better solution as it identifies multi-dimensional signatures which can better predict the risk of recurrence than histology. For example, in triple-negative breast cancer (TNBC), the combination of transcriptomic subtyping with deep proteomic profiling has uncovered a number of sub-phenotypes with differences in immune infiltration and metabolic flux, beyond the scope of conventional pathological diagnosis. Likewise, in CRC, the integrated risk scores based on the combination of chromosomal instability indices and metabolomic alterations in lipid pathways have been shown to be powerful predictive markers of disease free survival. For glioblastoma, the combination of epigenetic markers (e.g., MGMT promoter methylation) with transcriptomic data has identified correlations with survival independent of patient age and surgical margin status, emphasizing the need for comprehensive data to enable precision neuro-prognostics.

Precision Prediction of Treatment Response and Resistance

The ultimate goal of precision oncology is to move beyond trial-and-error medicine. While Precision oncology aims to go beyond 'one size fits all' drugs. Genomic biomarkers, such as the presence of EGFR mutations and ALK rearrangements, are known guides to targeted therapy, but they are not sufficient to explain the development of acquired resistance. Recent studies have focused on phosphoproteomic and kinomic signatures that reflect the dynamic and rapid transformation of signaling networks that are adaptive to TKI resistance, which is not apparent at the genomic level. The world of immunotherapy is changing fast and the ability to predict the response to immune checkpoint inhibitors (ICIs) relies on a multi-faceted approach, based on both tumor and host features. The combination of Tumor Mutational Burden (TMB) and transcriptomic markers of T-cell inflamed microenvironment and metabolic markers of tumor-induced acidity (such as lactate) results in a much more powerful predictive model than any single-omic measure. In addition, these layers are being combined in real-time using recent machine learning frameworks like ensemble deep learning to generate predictive scores. The adoption of these composite models into clinical care is still dependent on standardization of clinical validation in prospective large-scale clinical trials and harmonization of data governance procedures.

Clinical Laboratory Integration: From Research to Routine Practice

Beyond technological capabilities, the ability to transfer multi-omics signatures from discovery to regulated clinical environments requires carefully orchestrating the entire workflow and integrating it into the existing laboratory infrastructure. Eliminating and alleviating the "reliability" and "reproducibility" problems of high-dimensional data, as well as the "clinical actionability" issue for modern diagnostics, is the main challenge. The multi-omics workflow is extremely complicated and can cover a wide range of aspects, including sample stabilization, bio-informatic reporting and interpretation, and much more. In order to satisfy the requirements for a top-tier accreditation, including CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathologists), each phase needs to follow strict standards of professionalism.

The Critical Window: Sample Integrity and Pre-analytics

The garbage in, garbage out principle is enhanced in the multi-omics paradigm. The integrity of the sample is the most fundamental requirement for downstream accuracy because RNA, proteins, and metabolites are very volatile and are easily destroyed by biochemical degradation and cellular lysis. Even the delay in plasma processing, for example, can cause the breakdown of circulating tumour DNA (ctDNA) and the liberation of genomic DNA (gDNA) from white blood cells, preventing the detection of early cancer signals. In the same way, proteomic and metabolomic profiles are highly sensitive to temperature changes and the negative impact of repeated freeze-thaw cycles, which can cause shifts in the amount of less-stable metabolites such as lactate or some phosphoproteins. Strict Standard Operating Procedures (SOPs), immediate stabilization with special preservative tubes (such

as Streck tube, PAXgene tube), and timely cold-chain logistics are essential to ensure biological fidelity from various omics layers.

Harmonization and Standardization Frameworks

A key factor in enabling widespread clinical use of standardisation, across platforms and platforms, is to reduce inter-laboratory variation. The method validation and accreditation are based on international guidelines, specifically ISO 15189 (Medical laboratories Requirements for quality and competence). Certified reference materials (CRMs) and universal calibrators enable harmonization of various workflows, such as Next-Generation Sequencing (NGS) or high-resolution mass spectrometry. Moreover, the “dry-lab” bioinformatics pipelines should be standardized as well. It is essential to standardise normalization techniques, batch-correction algorithms, and the parameters used for variant calling across diagnostic centres, to generate interpretable and comparable results. There are ongoing collaborative efforts like the Sequence Quality Control Phase 2 consortium (SEQC2) to establish standards for the consistency of multi-omics data for regulatory submissions.

Rigorous Quality Control (QC) and Performance Tracking

The quality control of multi-omics is a multidimensional process that needs to be integrated into all steps of the analysis pipeline, from starting with nucleic acid extraction and library preparation to final data integration. For detection of instrument drift or reagent inconsistencies that could affect patient outcomes, the use of internal spike-in controls (ERCC RNA spikes or isotopic protein standards), technical replicates, and real-time process monitoring are a critical component. To ensure the accreditation requirements of a professional clinical laboratory, continuous performance monitoring is required, including External Quality Assessment (EQA) and proficiency testing (PT). Furthermore, AI-based diagnostic systems must be validated thoroughly, including through stress testing on a variety of clinical datasets, to avoid algorithmic bias and allow for the algorithm to be reproducible across different patient ethnicities.

Analytical Validation: Defining Precision and Sensitivity

Nevertheless, a multi-omics assay needs to be extensively analytically validated before it can affect a clinician's decision. This includes an official evaluation of accuracy, precision (reproducibility and repeatability), analytical sensitivity, analytical specificity and the limit of detection (LOD). Often validation studies require comparison to a well-established gold standard assay like digital PCR to confirm mutation detection, or immunohistochemistry (IHC) for protein expression. It is important to document assay performance for different batches and various laboratories to meet regulatory requirements for FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) standards. This stringent validation process not only guarantees reliability but also establishes the clinical significance and trustworthiness needed to inform clinical decisions that are critical for managing patients with cancer, including the choice of a particular tyrosine kinase inhibitor (TKI) or the decision for adjuvant chemotherapy.

Turnaround Time (TAT) and Clinical Utility

The time is of the essence in oncology; time to diagnosis can lead to upstaging or time loss. The Turnaround Time (TAT) for multi-omics biomarkers should be comparable to the clinical decision-making process, ideally within 7-10 days. High level automation (e.g. robotic liquid handlers), batch processing, and lean bioinformatics pipelines can minimize analytical delays without sacrificing quality. Finally, the intent is to show evidence of “Clinical Utility” which means that the multi-omics test directly improves the outcome of patients when compared to the standard of care diagnostics. This high speed and accuracy balance allows these cutting-edge diagnostics to deliver timely and actionable insights that can significantly influence patient management and long-term survival rates.

Summary Table: Laboratory Integration Challenges and Solutions

Table 2. This table summarizes the major operational challenges in implementing multi omics assays in clinical laboratories

Challenge	Impact on Clinical Testing	Recommended Solutions
Sample Preparation	Degradation of DNA/RNA/proteins/metabolites	Use preservatives, rapid stabilization, SOPs for handling and storage
Standardization	Inter-laboratory variability	ISO 15189, CLSI guidelines, calibrators, universal controls, standardized pipelines
Quality Control (QC)	Instrument drift, data inconsistency	Internal controls, replicates, continuous monitoring, software validation
Analytical Validation	Inaccurate or non-reproducible results	Assess accuracy, sensitivity, specificity, linearity; compare with gold standards
Turnaround Time (TAT)	Delay in clinical decision-making	Automation, batch processing, integrated bioinformatics pipelines




Figure 1. AI-powered, multi-omics precision oncology integrated system. This flow diagram shows that we collected biological samples such as blood, tissue, and biofluids, and that they go through high throughput molecular profiling and then through AI integration of data, toward clinically actionable insights. Parallel layers illustrate important translations issues such as analytical validation, economic considerations and regulatory requirements for potential routine clinical use

Analytical and Translational Challenges: The Research-to-Practice Gap

The wide application of multi-omics technology in the clinical routine is still hindered by multiple system bottlenecks even though technology has rapidly developed from high-end research to routine clinical usage. Beyond just the technological gap, there are also gaps in computational, economic, and regulatory aspects, making the widespread clinical adoption of these systems challenging.

Data Complexity and the "Noise" of Heterogeneity

The first analytical challenge is the natural complexity of high dimensional data. All omics layers, be it genomic, proteomic or metabolomic, have their own distinct statistical distribution, signal to noise ratio, and missing-value profile. These data modalities have to be brought together into a uniform, coherent biological signature, involving advanced normalization techniques to separate biologically relevant signals from technical artifacts. In addition, batch effect and platform-related biases can undermine the reproducibility of multi-omics signatures across the various diagnostic centers. This is accentuated by intratumoral heterogeneity, defined as the molecular diversity found within a single tumor biopsy sample, which can result in a biased molecular interpretation and make it difficult to share the interpretation of molecular markers between different patient cohorts.

Bioinformatics Infrastructure and Interpretability

Integrating multiple omics data is challenging and requires significant resources such as high-performance computing (HPC) and bioinformatics skills. One of the major challenges in this area is Overfitting, in which machine learning models are designed to predict the results of a specific discovery dataset, but fail to predict the results of a clinical situation. Although deep learning models provide high accuracy, they still have a black box characteristic that is a big hurdle for clinicians. Transparent and interpretable rationales for making diagnostic decisions are imperative. Additionally, there is no standardized, open-source pipelines to facilitate cross-study comparisons, which can hinder the ability of regulatory bodies to assess the consistency of these computational workflows.

Economic Viability and Reimbursement Barriers

One of the major challenges to scalability is the cost of multi-omics, which involves the use of costly reagents, high-end mass spectrometers, and highly-skilled personnel, especially in low-resource healthcare environments. To be included into clinical guidelines, a multi-omics panel should show "Incremental Value" over current, lower cost, and more readily available assays such as IHC or single-gene PCR. There is a current lack of comprehensive cost-effectiveness analyses with the use of realistic cost-effectiveness measures such as Quality-Adjusted Life Years (QALYs). If there is no clear health-economic evidence of benefits, patient access to such life-saving technologies is restricted by the lack of reimbursement for such third-party payers or insurance providers.

Regulatory Pathways and Validation Hurdles

The current regulatory frameworks (e.g. FDA, EMA) were established for assays of a single analyte, each with clear performance requirements. The challenge of adapting these frameworks to assess the performance of combinatorial, multivariate models is enormous. A paradigm shift is needed to approach Analytical Validation for an assay that integrates thousands of variables. In addition, most of the multi-omics findings are available for retrospective studies, and to become available in clinical practice, large-scale prospective clinical trials (e.g., umbrella or basket trials) will need to meet rigorous regulatory expectations.

Implementation Science: Closing the Translational Gap

Barriers to use can arise with an analytically flawless assay, including silo mentality among bioinformaticians, molecular pathologists and clinicians. Multi-omics research is frequently neglected in implementation science, the research of how to put evidence-based innovations into routine practice. An embedded approach is crucial to ensure that workflows are both scientifically sound and clinically viable within the fast moving clinical environment. The development of multidisciplinary Molecular

Tumor Boards is an essential component to take multi-omics data and make it into actionable treatment plans for individual patients.

Translational Challenges and Future Directions

Although the multi-omics technologies have made great strides in recent years, their adoption in the clinical setting is still complicated. The potential problem is the ability to integrate high dimensional biological data with the operational demands of diagnostic laboratories, including cost, turnaround time, regulatory compliance and clinical interpretability. In addition to technological improvements, coordinated developments in computational modelling, health economics and governance frameworks will be important to see progress over the next decade.

From Predictive Accuracy to Clinical Interpretability: The Role of AI

The incorporation of the genomics, proteomics and metabolomics data has become essential and is increasingly made possible by artificial intelligence (AI) and machine learning (ML). These methods are superior to conventional statistical models for modeling non-linear interactions and biological cross-layer dependencies. But it is not enough to be predictive to be used in clinical practice.

One of the drawbacks of deep learning systems is that they are not very interpretable. Transparency is needed for clinicians and regulators to obtain mechanistic plausibility, not opaque risk scores. Thus, Explainable AI (XAI) frameworks are vital to help bridge the gap between the outputs of algorithms and biologically relevant insights that can inform therapeutic decisions. If this is not transparent, multi-omics AI systems are likely to be stuck in the research lab.

Also crucial is dataset bias. Many existing training cohorts are under-representative of population diversity, and therefore are of concern for algorithmic generalizability. Future development will need to focus on multi-center validation and demographic diversity to have an equal diagnostic performance.

Economic Sustainability and Clinical Value

High costs of instrumentation, consumables, storage and bioinformatics skills are limiting the implementation of multi-omics platforms. Technological miniaturization and multiplexing strategies will decrease the amount of cost per sample, but the widespread use is ultimately dependent on clinical utility.

Prospective analyses of these health economics are needed to demonstrate the incremental benefit of multi-omics testing, especially in terms of Quality-Adjusted Life Years (QALYs) and avoiding ineffective therapies. If comprehensive molecular profiling can help avoid the unnecessary use of expensive immunotherapies, the savings in the downstream could be worthwhile and the costs of initial tests could be acceptable. Without strong cost-effectiveness information, reimbursement structures will not be able to facilitate the broad clinical integration.

Regulatory Adaptation and Ethical Oversight

Current regulatory frameworks were mainly developed for single analyte diagnostic testing. These are challenged by multi-omics assays, particularly those that incorporate an adaptive AI scoring system. There are emerging regulatory agency guidelines for AI-powered companion diagnostics, but there is limited harmonization of international guidelines.

The scientific validation of an analysis is not the only aspect that affects ethics. Problems with data ownership, informed consent to secondary data use, and algorithmic accountability should be tackled. Adopting AI in the diagnostic process brings up concerns about responsibility when AI-generated results affect clinical choices. When it comes to AI and diagnostics, there are concerns about responsibility when diagnosis is influenced by AI outputs. To ensure the responsible implementation, clear governance structure will require laboratory scientists, clinicians, regulators, and bioethicists to be involved.

Data Infrastructure, Security, and Federated Learning

Multi-omics diagnostics yield high volume and diversity of data that demand secure data storage and infrastructure interoperability. Laboratory Information Systems (LIS) should be able to

include standardized formats that integrate with other Electronic Health Records (EHR) seamlessly, including FHIR. The process of centralizing data is hindered by privacy laws, such as HIPAA and GDPR. This is where Federated Learning (FL) comes in, providing a potential solution that allows model training to occur while avoiding the sharing of data among institutions. This not only increases statistical power but also ensures regulatory compliance. However, federated models need to be well benchmarked to enable these models to be reproduced in other laboratories with different setups.

Toward Longitudinal and Real-Time Oncology Monitoring

Precision oncology is becoming a more longitudinal and less static approach. Circulating tumor DNA (ctDNA) is another potential surveillance tool that may be used for earlier detection of therapeutic resistance than conventional imaging modalities. Advances in miniaturization of so-called “lab-on-a-chip” platforms and wearable biosensors hold promise of bringing molecular monitoring beyond the confines of centralized laboratories. These tools have the transformative ability, but their analytical sensitivity, standardization, and clinical validation continue to be challenges. To achieve broad clinical use, reproducibility would need to be demonstrated, thresholds would need to be established, and the use of the tool would need to fit into existing care pathways.

Conclusion

A move towards systems level oncology is clear from multi-omics biomarker research. This enables a more precise diagnosis, more accurate prognostic stratification and better personalized treatment decisions, as it combines genomic, proteomic, metabolomic and epigenomic data. Although these advances have been made, there has not been an equivalent transition to everyday clinical practice. Common issues include data heterogeneity, the interpretability of algorithms, cost constraints, requirements for infrastructure, and harmonizing laboratory workflows. These barriers can only be overcome with concerted actions taken by laboratory scientists, clinicians, computational experts, health economists and regulators. Integrative modeling and decision-support systems are likely to be key technologies for operationalizing multi-omics diagnostics in the future, with the help of artificial intelligence. But it will take transparency and reproducibility, and thorough validation of the clinical trust, across patient populations. Likewise, molecular monitoring longitudinally may be a useful platform for personalized oncology treatment, but needs to be standardized and have clear clinical utility endpoints. The next step of advancement will not be about technology but about implementation plan. Multi-omics will move from an advanced research paradigm to a routine part of oncology diagnostics if they can be successfully implemented by scalable laboratory automation, interoperable data systems, economic validation, and regulatory alignment. Successful integration of multi-omics could revolutionize precision oncology, not in replacing current clinical paradigms, but in augmenting them with molecular resolution and more precise therapeutic direction.

REFERENCES

- [1] R. Aebersold *et al.*, “How proteomics is reshaping the landscape of clinical diagnostics,” *Nature Reviews Methods Primers*, vol. 2, no. 1, p. 45, 2022.
- [2] F. M. Al-Daffaie *et al.*, “Exosomal biomarkers in cancer: Insights from multi-OMIC approaches,” *Clinica Chimica Acta*, vol. 579, p. 120606, 2026.
- [3] S. B. Baylin *et al.*, “The fundamental role of epigenetic alterations in cancer and clinical utility,” *Nature Reviews Cancer*, vol. 22, no. 12, pp. 685–698, 2022.
- [4] M. Brown *et al.*, “Metabolic and transcriptomic predictors of immunotherapy response,” *Cancer Cell*, vol. 42, no. 1, pp. 45–60, 2024.
- [5] D. Cheng *et al.*, “Clinical applications of NGS-based mutation panels in oncology,” *Journal of Molecular Diagnostics*, vol. 25, no. 4, pp. 440–453, 2023.
- [6] C. Curtis *et al.*, “Proteogenomic prognostic signatures in triple-negative breast cancer,” *Nature Communications*, vol. 14, no. 1, p. 868, 2023.

- [7] W. Gao *et al.*, "Wearable biosensors and PoC diagnostics for real-time cancer monitoring," *Nature Electronics*, vol. 8, pp. 112–128, 2026.
- [8] M. Graf *et al.*, "Cost-effectiveness of multi-omics panels in precision oncology," *Journal of Clinical Oncology*, vol. 42, no. 15_suppl, p. e22510, 2024.
- [9] R. Gupta *et al.*, "Machine learning integration of multi-omics for therapy response prediction," *Bioinformatics*, vol. 41, no. 5, pp. 1234–1245, 2025.
- [10] Y. Hasin *et al.*, "Multi-omics approaches to disease," *Genome Biology*, vol. 18, p. 83, 2023.
- [11] J. L. Jaremko *et al.*, "Implementation science in oncology: Closing the gap," *Nature Reviews Cancer*, vol. 24, pp. 110–125, 2024.
- [12] Z. Jiang *et al.*, "Multi-omics strategies for biomarker discovery and application in personalized oncology," *Molecular Biomedicine*, vol. 6, no. 1, p. 115, 2025.
- [13] K. M. Joo *et al.*, "Epigenetic and transcriptomic integration in glioblastoma survival," *Neuro-Oncology*, vol. 26, no. 4, pp. 610–625, 2024.
- [14] G. Kaissis *et al.*, "Federated learning for privacy-preserving clinical diagnostics," *Nature Machine Intelligence*, vol. 6, pp. 15–30, 2024.
- [15] H. J. Lee *et al.*, "Phosphoproteomic landscapes of drug resistance in melanoma," *Nature Cancer*, vol. 5, no. 2, pp. 210–225, 2024.
- [16] A. M. Lennon *et al.*, "Feasibility of blood-based multi-omics for early cancer detection," *Science*, vol. 369, no. 6510, p. eabb9601, 2022.
- [17] X. Li *et al.*, "Pre-analytical challenges in clinical metabolomics and proteomics," *Clinical Chemistry*, vol. 69, no. 3, pp. 210–225, 2023.
- [18] M. H. Lin and Z. Q. Chen, "Epigenomic biomarkers for early cancer detection: Multi-omics integration," *Epigenetics*, vol. 19, no. 4, pp. 325–342, 2024.
- [19] Y. Liu *et al.*, "Composite multi-omics panel for pan-cancer early detection," *Cell*, vol. 184, no. 3, pp. 615–632, 2025.
- [20] A. M. Newman *et al.*, "Circulating tumor DNA and MRD monitoring in oncology," *Nature Medicine*, vol. 28, no. 5, pp. 1105–1114, 2022.
- [21] W. S. Noble *et al.*, "Statistical challenges in integrating multi-omics data," *Nature Methods*, vol. 21, no. 4, pp. 512–525, 2024.
- [22] A. Rajkomar *et al.*, "Explainable AI (XAI) in clinical diagnostics: Bridging the trust gap," *Nature Medicine*, vol. 31, no. 2, pp. 410–425, 2025.
- [23] N. E. Sharpless *et al.*, "Regulatory challenges for AI-driven multi-omics diagnostics," *Science Translational Medicine*, vol. 17, no. 740, p. eab1234, 2025.
- [24] A. Snyder *et al.*, "Clinical multi-omics: Transition from research to practice," *Journal of Clinical Investigation*, vol. 133, no. 12, p. e166011, 2023.
- [25] L. Tian *et al.*, "Single-cell and spatial omics in cancer research," *Cell*, vol. 187, pp. 512–530, 2024.
- [26] E. J. Topol *et al.*, "The era of AI-integrated clinical medicine," *The Lancet*, vol. 403, no. 10430, pp. 915–930, 2024.
- [27] B. Tran *et al.*, "Implementation requirements for multi-omics predictive models in clinical labs," *Clinical Chemistry and Laboratory Medicine*, vol. 62, no. 7, pp. 1048–1060, 2024.
- [28] B. Vogelstein *et al.*, "Cancer genome landscapes and the future of molecular diagnostics," *Nature*, vol. 625, pp. 23–35, 2024.
- [29] J. Wang *et al.*, "Circulating tumor DNA methylation as a liquid biopsy biomarker for cancer detection," *Journal of Clinical Oncology*, vol. 42, no. 10, pp. 1015–1025, 2024.
- [30] D. S. Wishart *et al.*, "Metabolomics and its role in early cancer detection: A clinical review," *CA: A Cancer Journal for Clinicians*, vol. 74, no. 2, pp. 142–160, 2024.
- [31] C. Cimino *et al.*, "Nanoparticles as a strategy to overcome the barriers of cancer treatment," *Cancers*, vol. 15, no. 11, p. 2890, 2023.
- [32] N. Gómez-Cebrián *et al.*, "Multi-omics: The next step in precision medicine and clinical laboratory diagnostics," *International Journal of Molecular Sciences*, vol. 23, no. 21, p. 13521, 2022.

- [33] P. Tasca *et al.*, "Application of spatial omics to the classification of kidney biopsy samples in transplantation," *Nature Reviews Nephrology*, 2024. doi: 10.1038/s41581-024-00861-x.
- [34] J. M. Edayan *et al.*, "Integration technologies in laboratory information systems: A systematic review," *SSRN*, 2024. doi: 10.2139/ssrn.4750694.
- [35] V. Barresi, "The crucial findings derived from the special issue 'Inside cancer genomics: From structure to therapy,'" *Cancers*, vol. 15, no. 13, p. 3488, 2023.
- [36] A. Mosteller and A. Masood, "Clinical applications of next-generation sequencing for cancer diagnostics and targeted cancer therapy," *Proceedings of IMPRS*, 2024. doi: 10.18060/27747.
- [37] Kim, "Immunotherapy for microsatellite-stable colorectal cancer: Overcoming resistance and exploring novel therapeutic strategies," *Annals of Coloproctology*, 2026. doi: 10.3393/ac.2025.01354.0193.
- [38] C. W. Hu and A. A. Qutub, "Proteomics in acute myeloid leukemia," in *IntechOpen*, 2017. doi: 10.5772/intechopen.70929.
- [39] S. R. Savage *et al.*, "Pan-cancer proteogenomics expands the landscape of therapeutic targets," *Cell*, 2024. doi: 10.1016/j.cell.2024.05.039.
- [40] D. Whitby *et al.*, "Developing cerebrospinal fluid metabolomic biomarkers for minimal residual disease and relapse in ependymoma and medulloblastoma," *Neuro-Oncology*, vol. 26, suppl. 7, pp. vii2–vii2, 2024.
- [41] S. Zhang *et al.*, "DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues," *Nature Communications*, vol. 14, no. 1, 2023.
- [42] P. Olson and J. R. Wagner, "Established and emerging liquid biomarkers for prostate cancer detection: A review," *Urologic Oncology*, 2024. doi: 10.1016/j.urolonc.2024.05.011.
- [43] J. Techau, "Using all our genomes: Blood-based liquid biopsies for the early detection of cancer," *VIEW*, vol. 3, no. 1, p. 20200118, 2022.
- [44] J. G. Lee *et al.*, "Integrating E-cadherin expression levels with TNM staging for enhanced prognostic prediction in colorectal cancer patients," *BMC Cancer*, vol. 25, no. 1, 2025.
- [45] S. K. Arviola, "Cracking cancer's drug resistance code: How omics is shaping the future of precision medicine," *Health Science Inquiry*, vol. 14, pp. 20–23, 2025.
- [46] P. van der Leest and E. Schuurin, "Critical factors in the analytical workflow of circulating tumor DNA-based molecular profiling," *Clinical Chemistry*, vol. 70, no. 1, pp. 220–233, 2024.
- [47] M. Outaki *et al.*, "Reference materials: A review," *Journal of the Turkish Chemical Society Section A: Chemistry*, 2024. doi: 10.18596/jotcsa.1361004.
- [48] A. Krishnan *et al.*, "Machine learning for multi-omics data integration in cancer," *Nature Reviews Genetics*, 2024. doi: 10.1038/s41576-024-00695-x.
- [49] R. Heery *et al.*, "Clinical implementation of multi-omics: A framework for standardization and evidence-based integration," *The Lancet Oncology*, 2025. doi: 10.1016/S1470-2045(25)00088-4.